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Abstract 
 
Gabapentin has non-linear pharmacokinetics which limit its clinical effectiveness. The 
absorption of gabapentin occurs by L-amino acid transport system through a low-
capacity nutrient transporter expressed in a narrow part of the upper small intestine. 
This is a carrier-mediated and saturable transport system leading to dose-dependent 
pharmacokinetics of gabapentin- as the dose increases, the bioavailability decreases. 
 
Based on Kirby`s enzyme model, three gabapentin prodrugs were proposed. They are 
expected to have higher and predictable bioavailability, in contrast to gabapentin, as a 
result of improving passive absorption. Moreover, the proposed prodrugs can be used in 
different dosage forms due to their potential solubility in organic and aqueous media. 
The prodrugs were synthesized and characterized by melting point, fourier transform 
infrared spectroscopy, proton nuclear magnetic resonance spectroscopy and liquid 
chromatography-mass spectrometry analytical techniques to guarantee pure gabapentin 
prodrugs. Hydrolysis of gabapentin prodrugs was investigated using high-performance 
liquid chromatography at constant temperature (37
o
C) using different buffer pHs, 
namely, 0.1N HCl, pH 3, pH 6.8 and pH 7.4 to resemble the physiological environments 
in the human body. Furthermore, in silico prediction of physiochemical parameters, 
absorption, distribution, metabolism, excretion, toxicity, and blood-brain barrier 
permeability for the three synthesized gabapentin prodrugs were studied.   
 
Gabapentin prodrug 1 experimental half-life values in 0.1N HCl, buffer pH‘s 3, 6.8 and 
7.4 were 16.57, 17.76, 101.91, and 119.48 hours, respectively. 
iv 
 
 Gabapentin prodrug 2 was hydrolyzed into its parent drug in 0.1N HCl, buffer pH‘s 3, 
6.8, and 7.4 with experimental half-life values of 20.3, 22.70, 130.75 and 277.2 hours, 
respectively. However, gabapentin prodrug 3 was extremely insoluble in acidic 
environment and completely stable at pH 6.8 and pH 7.4. The in silico results revealed 
that all  the synthesized gabapentin prodrugs comply with Lipinski‘s rule of five, have 
good and favorable pharmacokinetic properties, have positive central nervous system 
permeability, and none of the prodrugs had high risk of toxicity.  
 
Three gabapentin prodrugs were synthesized and characterized and their in vitro 
intraconversion to their parent drugs showed that half-life was primarily affected by the 
pH of the medium, the distance between the two reactive centers, and the pka of the 
linker. In vivo pharmacokinetic studies will be done for both gabapentin prodrug 1-2 in 
order to determine the bioavailability and the duration of action of the tested prodrugs. 
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Chapter one 
1. Introduction 
1.1 Neuropathic pain 
 
Neuropathic pain is triggered by damage of the somatosensory nervous system affecting 
both its function and structure and leading to sudden onset of pain as well as 
pathological amplification of responses to innocuous and noxious stimuli [1]. It is 
commonly described as pricking, tingling, burning, coldness, itching, or stabbing [2-4]. 
Many animal studies of a neuropathic pain model showed alteration of voltage-gated 
sodium and/or potassium channels, and increases in transient receptor potential 
vanilloid 1 [5-7]. Also, the loss of gamma-aminobutyric acid (GABA) in the dorsal root 
ganglia after nerve damage contributes to the exaggerated response of nociceptive 
nerves of the spinal dorsal root ganglia [6]. 
 
It is estimated to distress millions of people worldwide [8-10], and also has a significant 
effect on health-related quality of life and is associated with high economic burden for 
the individual and society [11,12]. 
 
1.1.1.  Types of neuropathic pain: 
 
Neuropathic pain may result from dysfunctions of the central nervous system (CNS) or 
the peripheral nervous system. Therefore, neuropathic pain can be classified into 
central, peripheral, or mixed (central and peripheral ) neuropathic pain [13].  
3 
 
Central neuropathic pain frequently generates from spinal cord injury, stroke, or 
multiple sclerosis [13,14]. Peripheral neuropathic pain results from a multitude of 
conditions, including diabetes and other metabolic diseases, mechanical trauma, human 
immunodeficiency virus-related neuropathies, herpes zoster infection, neurotoxic 
chemicals, nutritional deficiencies, immune-mediated dysfunctions or tumor invasion 
[13,15,16].  
 
While there are many types of neuropathic pain according to the cause of nerve injury, 
such as the aforementioned, common types include: 
 
1.1.1.1. Diabetic neuropathy: 
 
Diabetic neuropathy is a serious and most frequent chronic complication of diabetes 
mellitus [17]. Chronic hyperglycemia results in activation of several metabolic 
pathways in the peripheral nervous system, including increased activity of polyol 
pathway in neurons and Schwann cells [18], and increased protein kinase C activity. 
These metabolic disturbances induced oxidative stress, which is a mediator of 
hyperglycemia causing sensory neuron injury and consequently diabetic neuropathy 
[19]. 
1.1.1.2. Post-herpetic neuralgia: 
 
Post-herpetic neuralgia is chronic pain caused by virus-induced nerve injury. It is the 
most common complication of herpes zoster and frequently results in significant 
reduction in the patient's health-related quality of life [20]. Approximately 20–35% of 
the population will develop herpes zoster in their life [21,22]. 
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About 10-30% of individuals with herpes zoster will experience post-herpetic neuralgia 
[23,24]. It is well known that herpes zoster affects the central and peripheral nervous 
systems [2].  
1.1.1.3. Trigeminal neuralgia: 
 
Trigeminal neuralgia is a chronic, painful disorder involving the trigeminal nerve. There 
are two divided trigeminal nerves, which carry sensation from face to brain, one on each 
side of the face. There are two types: typical and atypical trigeminal neuralgia [26]. The 
typical form is characterized by episodes of sudden, severe pain on one side of the face 
which last for seconds and up to a few minutes. The atypical form is characterized by 
less severe constant burning pain. The same person may experience both forms [27]. 
Most frequently the trigeminal neuralgia is induced by demyelination of trigeminal 
sensory fibers. The demyelination of trigeminal nerve root is usually caused by 
compression by an overlying artery or vein, multiple sclerosis, and compressive masses 
in the posterior fossa [28]. 
 
1.1.2.  Pharmacologic treatment of neuropathic pain: 
 
Neuropathic pain is commonly nonresponsive to typical analgesics [29]. Moreover, 
there is no evidence that refutes or supports the efficacy of paracetamol and non-
steroidal anti-inflammatory drugs for the management of neuropathic pain [30]. On the 
other hand, moderate to very low evidence demonstrates the efficacy of high 
concentration topical capsaicin (8%) to treat post-herpetic neuralgia, human 
immunodeficiency virus neuropathy, and painful diabetic neuropathy [31].  
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Moreover, according to a Cochrane review in 2018, there was no convincing evidence 
that supports the efficacy of opioids for the management of neuropathic pain [32-34]. In 
addition, there is uncertain evidence for the benefit from low concentration topical 
capsaicin or a topical lidocaine patch for neuropathic pain [35,36]. However, there is 
strong evidence for the efficacy and recommendations for the use of these three drug 
classes as first-line therapy in neuropathic pain [37]: the serotonin-nor-epinephrine 
reuptake inhibitors such as duloxetine [38-40], tricyclic antidepressants (TCAs), 
particularly amitriptyline [41], and the calcium channel alpha-2-delta ligands gabapentin 
and pregabalin were also recommended [42-44]. 
 
1.1.2.1. Tricyclic antidepressants:  
 
TCAs have demonstrated analgesic efficacy in both depressed and non-depressed 
patients with neuropathic pain [45]. The major advantages of TCAs are their once-daily 
dosing, low cost, and favorable effects on depression, which is a common complication 
of neuropathic pain [46]. However, the main drawback of TCAs is the risk of 
anticholinergic side effects and orthostatic hypotension [47]. In addition, cardiac 
toxicity is another disadvantage of  TCAs, therefore, it is recommended to use TCAs 
with caution in patients with cardiac disease [48,49]. 
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1.1.2.2. Selective serotonin and nor-epinephrine reuptake inhibitors: 
 
In many randomized clinical studies, two selective serotonin and nor-epinephrine 
reuptake inhibitors duloxetine, and venlafaxine have demonstrated efficacy in patients 
with peripheral neuropathic pain [50]. Duloxetine efficacy has been demonstrated to be 
continued over one year in painful diabetic peripheral neuropathy [51]. 
 The biggest advantages of duloxetine are its once-daily dosing and that it effectively 
treats depression [52]. The most common reported side effects of duloxetine were 
nausea, dry mouth, fatigue, dizziness, and constipation [53]. 
 
Venlafaxine also has demonstrated efficacy in diabetic peripheral neuropathy and 
polyneuropathies of variant causes, but not in post-herpetic neuralgia [54]. It should be 
used with caution in patients with cardiovascular disease since it is has been shown to 
be cardiotoxic in a small number of patients [55]. Many studies demonstrated a 
relationship between antidepressant treatment and thoughts of suicide. Therefore, 
concerns regarding the risks of TCAs and selective serotonin and nor-epinephrine 
reuptake inhibitors must be balanced versus the benefits in patients with neuropathic 
pain [56,57]. 
 
1.1.2.3. Calcium channel alpha 2-delta ligands: 
 
In spite of gabapentin and pregabalin being structural analogs to GABA, (see Figure 1-
1), they have no effect on the GABAergic system. They bind to voltage-gated calcium 
channels alpha 2-delta-1 subunit and antagonist it, inhibiting the release of excitatory 
neurotransmitters.  
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Both medications have been shown to be efficacious in many neuropathic pain 
conditions [58,59]. However, post-marketing surveillance has noted an increasing 
number of reports of heart failure in patients using pregabalin, but not gabapentin [60-
62].  
 
 
Figure ‎1-1: Chemical structure of gabapentin (a), pregabalin (b), and GABA (c). 
 
1.2 Epilepsy 
 
Epilepsy is a common, non-contagious, chronic, neurological, and heterogeneous 
collection of disorders affecting about 65 million people globally [63]. It is 
characterized by repeated incident of involuntary movements and unusual sensations 
accompanied by loss of awareness or not. The resulting recurrent seizure can be 
classified into either focal (partial) including only part of the body, or generalized, 
involving entire body which constitutes many types such as absence, atonic, myoclonic, 
and tonic-clonic seizures [64].  
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There is evidence from a review including  91 articles on gabapentin that gabapentin has 
efficacy as mono-therapy in adults and adolescents with newly recognized partial or 
mixed seizure diseases [65, 66]. Moreover, the discontinuation rate as a result of side 
effects was lower among patients on higher doses of gabapentin (13.5%) than those on 
carbamazepine (24%) [65]. 
 
1.3 Restless leg syndrome (RLS) 
 
RLS is a common neurological disease which is characterized by an urgent need to 
move the legs to alleviate unpleasant, not usually painful, and uncomfortable sensations 
[67]. The symptoms appear during the night or on rest particularly when lying or sitting 
[68]. It is divided into idiopathic and symptomatic (secondary) forms of RLS with the 
symptomatic form being associated with e.g. Parkinson‘s disease, iron deficiency, 
uremia, pregnancy, or chronic renal failure [68]. In 2016, evidence-based 
recommendations for the treatment of RLS were established. The alpha 2-delta ligands 
such as pregabalin and gabapentin were recommended for initial RLS management; 
these medications are effective and have a low risk of RLS augmentation [2]. Although 
dopaminergic drugs like levodopa and dopamine agonists are effective over the short-
term, their efficacy declines in many patients over time, and/or augmentation develops 
[69].  
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1.4  Gabapentin 
 
Gabapentin is l-(aminomethyl)cyclohexaneacetic acid structurally resembling GABA, 
an inhibitory neurotransmitter that was shown to have a role in managing seizure states 
[70]. It antagonizes voltage-gated calcium channels by binding to them [71]. It is a 
zwitterion with two pKa values: pka1=  3.68 (carboxylic acid)  and pka2= 10.70 
(primary amine) [72], not metabolized by human and thus, excreted renally unchanged, 
has a short half-life (t½), and has non-linear pharmacokinetic which limits its clinical 
effectiveness [73]. Therefore, its bioavailability differs inversely with dose. For 
example, the bioavailability of a 300-mg dose is roughly 60%, while that of a 600-mg 
dose is roughly 40%. When the dose is tripled from 300 to 900 mg, its maximum 
concentration increases less than three times as a consequence of dose-dependent 
saturable absorption [71]. Additionally, the absorption of gabapentin varies from patient 
to patient [71]. Gabapentin first received approval for use as an anti-epileptic 
medication in 1993 [74]. Then in 2002, it received approval as a treatment for post-
herpetic neuralgia [74]. Now, it has approval for the treatment of several types of 
neuropathic pain, epilepsy and RLS [69]. It is well tolerated but can cause dose-related 
dizziness and sedation [75]. 
 
1.5  Prodrug 
 
The term ‗prodrug‘ was first introduced by Albert in 1958 as a pharmacologically 
inactive moiety that undergoes conversion to its active form by metabolic and/or 
chemical processes prior to their therapeutic activity [76,77].  
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This term has been successfully used to alter the physicochemical, pharmacokinetic, and 
biopharmaceutical properties of the compound [78]. Thus, instead of designing and 
development of new chemical entities, which requires a lot of time and money [79], 
prodrug strategy can be used in order to modify the limitation and unfavorable 
physicochemical, biological, pharmacokinetic, and organoleptic properties of many 
existing medications [80]. 
 
About ten percent of all globally marketed drugs are considered as prodrugs. Between 
2000 and 2008, twenty percent of drugs that were approved were shown to be prodrugs 
and when considering 2008 alone, 33% of all approved drugs were prodrugs. 
Consequently, in the present time, the prodrug strategy became progressively more 
popular and successful in pharmaceutical industries [81,82]. 
 
1.5.1.  Applications of prodrug approach: 
 
1.5.1.1. Enhancing permeability and absorption: 
 
Absorption and permeability have an important effect on drug efficacy: improving the 
lipophilicity of the parent drug, by masking polarly ionized or nonionized functional 
groups, will increase either topical or oral absorption, this can be achieved by the 
prodrug approach [83]. Hydrophilic functional groups on the parent drug like amino 
groups can be changed to more lipophilic groups, and these prodrugs are easily 
hydrolyzed to parent drugs [84,85]. Furthermore, increasing oral absorption can be 
achieved by designing prodrugs that have the same structural properties of substrates 
that are taken up by carrier-mediated transport [86]. 
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1.5.1.2. Improving solubility and dissolution rate of drugs: 
 
When dissolution is the rate-limiting step in the absorption of poorly aqueous soluble 
agents or when the parental or ophthalmic formulation of such agents is desired, 
hydrophilicity or water solubility is required [87]. Higher than thirty percent of newly 
discovered drugs have low aqueous solubility and have low bioavailability [88,89]. In 
order to solve this limitation, several formulation strategies including salt formation and 
solubilizing excipients have been applied. However, prodrugs provide another strategy 
to enhance the solubility of the compound in the aqueous media by binding ionizable or 
polar neutral groups [86,90-91]. 
 
1.5.1.3. Taste masking: 
 
Bitterness and sourness of drugs are major reasons for a patient non-compliance and un-
acceptance, particularly pediatrics. In order to overcome the bad taste of the drug, two 
approaches can be utilized: i) reducing drug solubility in saliva and ii) masking 
functional groups that are possibly responsible for the drug‘s attaching to taste receptors 
located on the tongue [92]. 
 
1.5.1.4. Changing the distribution profile:  
 
In order to attain site-selective drug delivery, many efforts have been made to bind 
various macromolecular strategies and nanotechnologies, but these methods lack 
clinical success.  
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Today, the prodrug strategy is a promising site-selective drug liberation approach which 
utilizes endogenous enzymes and transporters of the target cell and tissue [86]. 
 
1.5.1.5. Protecting from rapid metabolism: 
 
The beneficial effects of drugs can be impaired by extensive excretion and\or metabolic 
pathways. Oral bioavailability of many drug molecules is significantly reduced by first 
pass metabolism [93]. Therefore, many formulation such as sublingual and controlled 
release have been designed to overcome this drawback [94]. However, oral 
bioavailability can be increased by masking metabolically sensitive functional groups 
using prodrug strategy [95]. 
 
1.5.2.  Enzymatically versus chemically bioactivation: 
 
Prodrugs that are designed to be activated by natural enzymes such as esterases and 
amidases are susceptible to individual variation in the response to pharmacologic 
therapies due to genetic polymorphisms of these enzymes [96]. 
 
Recently, many studies have shown that the presence of functional genetic variants of 
carboxylesterases: carboxylesterase 1 and carboxylesterase 2 alters the pharmacokinetic 
and pharmacodynamic properties of several prodrugs [96]. Several studies suggested 
that the genetic variants of carboxylesterase 1 may be linked with increased plasma 
concentrations of clopidogrel and may elevate the risk of toxic or adverse side effects 
[96,97]. 
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In addition, other studies demonstrated that genetic variants of carboxylesterase 1 and 
carboxylesterase 2 may decrease the activation of oseltamivir and irinotecan prodrugs, 
and obstruct prodrug activation, which may result in a decrease of the prodrugs‘ 
therapeutic effect [96,98-100]. Furthermore, seventy-five percent of enzymatically 
metabolized prodrugs are activated by cytochrome P450 enzymes [101], which are 
known to have genetic polymorphisms that lead to differing in prodrug effectivity and 
safety [102]. Moreover, the bioavailability and efficacy of prodrugs that are developed 
to liberate the active drugs by these natural enzymes may be reduced by premature 
hydrolysis during the absorption phase [103]. Consequently, the prediction of enzymatic 
hydrolysis of the prodrug becomes difficult and therefore clinical efficacy of the 
prodrugs will be unpredictable. Furthermore, bioconversion can be altered by a variety 
of factors like age, ethnicity, health, and gender [104-106]. 
 
Novel prodrugs for drugs having hydroxyl, phenol, or amine functional groups have 
been designed by employing recent computational process using molecular orbital and 
molecular mechanics methods. Most recently, Karaman‘s group have been computed 
many mechanisms of intramolecular methods for several enzyme models and utilized 
them for designing many prodrug linkers [107-110]. 
 
The conventional prodrug strategy was concentrated on affecting several 
physiochemical properties, whereas recent computational strategies work by designing 
prodrugs with a higher bioavailability than parent drugs by binding it with a suitable 
linker. The active drug will be released in a sustained manner when introduced to the 
physiological environment with the ability to control the release rate of the parent drug 
by binding the drug with different linkers [111]. 
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1.6 Problem statement 
 
Gabapentin has pharmacokinetic drawbacks which limit its clinical effectiveness. The 
absorption of gabapentin occurs by the L-amino acid transport system, due to its 
zwitterionic nature, through a low-capacity nutrient transporter expressed in a narrow 
part of the upper small intestine [73,112]. This is a carrier-mediated, and saturable 
transport system leading to the dose-dependent pharmacokinetics of gabapentin: as the 
dose increases, the bioavailability decreases [73]. For example, the bioavailability of 
gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 
2400, 3600, and 4800 mg per day taken in 3 divided doses, respectively [113,114]. All 
of these doses are within the recommended therapeutic dose range. For example, the 
recommended dose of gabapentin to treat epilepsy is 900 to 4800 mg divided three 
times per day [115].  Moreover, the saturable transport system led to variability of 
absorption of gabapentin from patient to patient [113].  
 
As a consequence of these pharmacokinetic deficiencies of gabapentin, the prediction of 
its dose necessary to achieve an optimal therapeutic effect in a given patient is often 
difficult, and the desired treatment response may not be achieved. In addition, the short 
t½ of gabapentin (about 5–7 h) represents another limitation of its pharmacokinetics that 
necessitates frequent dosing which is a cause of noncompliance in epileptic patients and 
missed doses which can reduce clinical effectiveness [73,114]. 
On the other hand, the prodrug chemical strategy requiring enzyme catalysis has many 
disadvantages related to many intrinsic and extrinsic factors that can alter the catalysis 
process. Such as unpredictable clinical effects and safety of the most prodrug-activating 
enzymes owing to genetic polymorphisms, age-related physiological changes, or drug 
interactions [116].  
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Therefore, there is need to design new prodrugs of gabapentin that have potential for 
higher and predictable bioavailability than the current medication when given in 
different dosage forms, have the ability to be hydrolyzed to their parent drugs through 
intramolecular reaction and without any need for enzyme catalysis, and have the ability 
to liberate gabapentin in a controlled manner to solve the frequent dosing problem of 
gabapentin.  
 
1.7 Thesis objectives 
 
1.7.1.  General objectives: 
  
The main aim of this research was to synthesize prodrugs of gabapentin that have the 
potential of higher bioavailbility and linear pharmacokinetics and have the ability to be 
hydrolyzed chemically to gabapentin without the need for enzymes. 
 
In order to obtain this objective, the gabapentin prodrugs‘ physiochemical properties 
must have the following: (i) to have a moderate hydrophilic-lipophilic balance (HLB) 
value; (ii) to be soluble in the physiochemical environment; (iii) to give upon chemical 
hydrolysis non-toxic by-products. 
By having these properties, the following features are expected to be obtained: (i) high 
bioavailability and linear pharmacokinetic properties; (ii) predictable plasma levels; (iii) 
a chemically driven programmable release system that releases gabapentin in a 
sustained manner; and (iv) the capability to use these prodrugs in different dosage 
forms. 
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1.7.2.  Specific objectives: 
 
Specific objectives to our study were: 
1. To synthesize gabapentin prodrugs having the potential for dose-independent 
and higher bioavailability than gabapentin through binding it to different linkers. 
2. To characterize these prodrugs using different analytical techniques. 
3. To carry out in vitro kinetic studies for the synthesized gabapentin prodrugs at 
different pHs resembling physiological media. 
4. To study the physiochemical parameters, pharmacokinetics, drug-likeness, and 
toxicity properties of the synthesized gabapentin prodrugs by in silico 
computational software. 
5. To predict the ability of the synthesized prodrugs to cross the blood-brain barrier 
(BBB) by in silico software. 
 
1.8 Research questions 
1. Would it be possible to bind gabapentin to the linkers through chemical 
synthesis? 
2. Do the proposed gabapentin prodrugs have physiochemical features which could 
result in a high and dose-independent bioavailability? 
3. Would the synthesized prodrugs have the ability to liberate, in vitro, gabapentin 
in a programmable release manner?   
4. Do the synthesized gabapentin prodrugs have the potential to be designed in 
several dosage forms? 
5. Do the synthesized prodrugs penetrate BBB and have a favorable 
physiochemical and drug-like properties? 
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Chapter two 
2.  Literature review 
 
 
In 1973, Satzinger group began the GABA project to search for an epilepsy treatment. 
Their study was based on compensation of GABA to the brain by passive diffusion by 
preparing lipophilic GABA analogs because GABA itself can't penetrate the BBB when 
given systemically [117]. In 1975, Satzinger and co-workers prepared gabapentin and 
demonstrated its effectivity in many animal models of epilepsy. Despite that gabapentin 
has much higher lipophilicity when compared to GABA, it was shown later that it did 
not enter the CNS by passive diffusion as Satzinger and Hartenstien had initially 
envisioned [117]. In 1995, it was discovered that it penetrates the BBB by L-type amino 
acid transporter [118].  
 
Surprisingly, gabapentin demonstrates little or no interaction with GABA receptors and 
does not appear to alter GABA uptake, synthesis, or metabolism as had been initially 
imagined [119]. Most recently, it demonstrated that it exerts its effects by binding to the 
alpha-2-delta-1 subunit of voltage-gated calcium channels and causes reduced calcium 
influx, decreasing the release of many excitatory neurotransmitters including glutamate 
[120]. This explained its effect as an anti-epileptic and analgesic of neuropathic and 
other conditions [120,121]. 
 
Later, pregabalin demonstrated its effectiveness for the treatment of epilepsy and 
neuropathic pain through the same mechanism of action as gabapentin, by coupling to 
the alpha-2-delta-1 subunit of voltage-gated calcium channels [58,122], but with higher 
and more predictable bioavailability [123]. 
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However, gabapentin is less addictive than pregabalin. Unlike gabapentin, pregabalin is 
scheduled as a schedule V controlled substance [124]. Pregabalin use is associated with 
increased risk of heart failure a side effect that has not been appeared with the less 
potent calcium channel antagonist gabapentin [60,62]. In addition, in 2017, Agarwal et 
al. showed that gabapentin is significantly more efficacious than pregabalin in reducing 
pain in chronic pelvic pain syndrome patients [125]. Moreover, pregabalin, like 
gabapentin, has a short t½ so it is required to be taken in 2 or 3 divided doses daily 
[126,127]. 
 
Many attempts have been made to synthesize prodrugs of gabapentin in order to 
overcome its pharmacokinetic limitations (previously mentioned) which include dose-
dependent pharmacokinetics for example, the bioavailability of a 300-mg dose is about 
60% while that of a 600-mg dose is about 40% [128,129],  high interpatient variability 
[113], and potentially ineffective drug exposure as a result of saturable gabapentin 
absorption that occurs only in a limited region of the small intestine by L-amino acid 
transport system through a low-capacity nutrient transporter [73,112]. Moreover, its 
short t½ requires frequent dosing leading to non-compliance in patients [114]. 
 
2.1 Novel gabapentin prodrugs classified according to their transporter target 
 
2.1.1. Gabapentin prodrug that targets high-capacity nutrient transporters: 
 
XP13512 [1-({[({1-[(2-methylpropanoyl)oxy]ethyl}oxy)carbonyl]amino}methyl) 
cyclohexyl] acetic acid)) is gabapentin enacarbil (Figure 2-1). It was synthesized as a 
gabapentin prodrug [130].  
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It is an actively transported prodrug that overcomes the pharmacokinetic drawbacks of 
gabapentin through absorption by  high-capacity nutrient transporters, monocarboxylate 
transporter-1, and sodium-dependent multivitamin transporter, which are located all 
over the large and small intestine [128]. Therefore, it provides predictable dose-
proportional gabapentin exposure with higher (≥68%) oral bioavailability [130]. In 
April 2011, the Food and Drug Administration approved gabapentin enacarbil 600 mg 
once daily for the management of RLS [131]. In June 2012, gabapentin enacarbil 1,200 
mg/day (600 mg twice daily) also received approval by Food and Drug Administration 
for the treatment of post-herpetic neuralgia [131,132]. 
 
HO
O
N
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O
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Figure ‎2-1   : Chemical structure of gabapentin enacarbil. 
 
However, gabapentin enacarbil is hydrolyzed to gabapentin after being absorbed by 
nonspecific carboxylesterases present primarily in enterocytes [133]. Recent studies 
demonstrated that genetic variants of carboxylesterase 1 and carboxylesterase 2 may 
reduce the activation of many prodrugs that are metabolized by carboxylesterases 
[98,99]. Thus, the activation of gabapentin enacarbil to gabapentin might be susceptible 
to individual variation due to genetic polymorphisms of carboxylesterases [96].  
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2.1.2.  Gabapentin prodrugs that target the human apical sodium-dependent bile 
acid transporter (hASBT): 
 
An alternative approach employed by Polli and coworkers was coupling gabapentin to a 
natural substrate of a transporter to yield several novel prodrugs to enhance gabapentin 
absorption through targeting high-capacity membrane transport systems in the gut 
[129]. Since the main limitation in gabapentin absorption results from its zwitterionic 
nature and its facilitated uptake by low-capacity transporters [73], these prodrugs were 
designed to target hASBT with the same high affinity and high capacity as native bile 
acids [129]. hASBT belongs to the solute carrier genetic superfamily, it is considered as 
an essential carrier protein expressed in the intestine. It mediates the intestinal 
absorption of bile salts through enterohepatic circulation [134], and many studies 
suggested it as potential prodrug target [135]. 
 
Five prodrugs were synthesized to which gabapentin was linked to chenodeoxycholic 
acid (CDCA) (Figure 2-2). These prodrugs differed in ionic properties and the existence 
or lack of glutamic acid linker between gabapentin and the bile acid. Among these 
prodrugs, only two were found to be likely prodrugs that may elevate gabapentin 
absorption via hASBT uptake: CDCA-gabapentin and CDCA-glutamic acid-gabapentin 
methyl ester which they represented in Figure 2-2 as A and D compounds, respectively. 
These two prodrugs where tested for their inhibition and uptake properties. The 
inhibition study with taurocholate showed that the gabapentin conjugates are potent 
inhibitors, with strong interaction with the transporter. Based on this study, the 
researcher concluded that these both derivates are novel prodrugs of gabapentin.  
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However, these two prodrugs were chemically stable but they degraded by a catalyst to 
gabapentin [129]. We need the prodrugs to be hydrolyzed chemically and not 
enzymatically because the activity of many prodrug activating enzymes may be varied  
due to: genetic polymorphisms, age-related physiological change and drug interactions. 
Therefore, the clinical response may be varied [116]. 
 
 
Figure ‎2-2  : Chemical structure of five gabapentin prodrugs that target the hASBT. 
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2.2 Enzyme models 
 
Prodrugs of gabapentin were utilized to provide gabapentin in adequate predictable 
concentrations and a controlled release manner. Although, some achievement has been 
obtained using diverse approaches in which, all synthesized gabapentin prodrugs are 
enzymatically converted to gabapentin, this prodrug chemical strategy requiring enzyme 
catalysis has several drawbacks as a result of several intrinsic and extrinsic factors. 
Drawbacks which can alter the transformation of the prodrug to its parent drug for 
instance; the activity of many prodrug-activating enzymes may differ as a result of age-
associated physiological changes, genetic polymorphisms, or drug interactions, causing 
differences in therapeutic response [116,136-138]. However, no attempt was made to 
develop prodrugs of gabapentin using the chemical approach to release the parent drug 
in a predictable and programmable manner [139]. 
 
Therefore, there is need to synthesize new prodrugs of gabapentin with higher and dose-
independent bioavailability which have the potential to release gabapentin in a sustained 
manner via intramolecular chemical conversion without the need for enzyme catalysis. 
 
Karaman‘s group have explored a number of intramolecular processes to gain insight 
into enzyme catalysis, toward the development of prodrug linkers with improved 
bioavailability over existing medications using ab initio and density functional theory 
molecular orbital methods [140-156]. They studied the proton transfer reaction in some 
of Kemp's acid amide derivatives 1-11 (Figure 2-3) by using enzyme models as 
potential linkers to be linked to amine-drugs [157].  
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Moreover, Kirby‘s group have studied the acid-catalyzed hydrolysis of  N-
alkylmaleamic acids 1-9 (Figure 2-4); they found that the intramolecular nucleophilic 
group is responsible for the amide bond cleavage [158].  
 
 
 
Figure ‎2-3  : Chemical structures of Kemp‘s acid amides 1-11. 
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Figure ‎2-4: Acid-catalyzed hydrolysis of N-alkylmaleamic acids 1-9. 
Based on density functional theory calculations of proton transfer mechanism of these 
acid amides, three gabapentin prodrugs were proposed (Figures 2-5 to 2-7). These 
proposed gabapentin prodrugs 1-3 (ProD 1-3) have a modified HLB, due to the 
presence of  both hydrophilic and lipophilic moieties. In addition, at physiological pH in 
the intestine and blood circulation, the calculated predominant form of gabapentin is the 
ionized form whereas ProD 1-3 are predicted to exist in the free acid and ionic forms. 
Thus, gabapentin ProD 1-3 were expected to have higher and more predictable 
bioavailability than gabapentin as a result of increased its passive absorption. 
 
 
 
 
Figure ‎2-5: Acid-catalyzed hydrolysis of gabapentin ProD 1. 
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Figure ‎2-6: Acid-catalyzed hydrolysis of gabapentin ProD 2. 
 
 
 
 
 
 
Figure ‎2-7: Acid-catalyzed hydrolysis of gabapentin ProD 3. 
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Chapter Three 
 
3. Experimental Part 
 
This chapter consists of four main parts: Part one describes all material, chemicals, and 
instruments used in this study. The second is the synthetic part which concerns with the 
synthetic methods and identification of the synthesized prodrugs. Third one is the 
kinetic studies part that illustrates the specific preparations and analysis used to study 
gabapentin prodrugs intraconversion in different four potential of hydrogen (pH 
solutions by the high-performance liquid chromatography (HPLC). The fourth part is an 
in silico prediction of the physiochemical parameters, drug-likeness, ADMET 
(absorption, distribution, metabolism, excretion, and toxicity) properties, and CNS 
penetrability of the synthesized prodrugs. 
 
3.1 Part one 
 
3.1.1.  Chemicals and Instrumentation: 
 
3.1.1.1. Reagents: 
 
A pure standard of gabapentin was obtained from Beit Jala Pharmaceutical Company. 
The diastereomeric mixture  of hexahydro-4-methylphthalic anhydride, cis-1,2-
cyclohexanedicarboxylic anhydride, mixture of diastereomers of camphoric acid 
anhydride, sodium hydroxide (NaOH) and thin layer chromatography were all 
purchased from Sigma Aldrich. 
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3.1.1.2. Solvents: 
 
Tetrahydrofuran (THF), hexane, chloroform, and diethyl ether were all obtained from 
Sigma Aldrich. Distilled water was obtained from a distillatory device available at 
Karaman‘s lab. HPLC grade solvents of methanol, acetonitrile, and water were 
purchased  
from J.T. Paker. 
 
3.1.1.3. Instrumentation and substance identification: 
 
Chemical hazards fuming hood, hotplates, pH meter and rotary evaporator are available 
at Karaman‘s Lab in the Faculty of Pharmacy, Al-Quds University. The melting point 
and FT-IR were done at Beit Jala Pharmaceutical Company in Bethlehem. HPLC was 
done at Beit Jala Pharmaceutical Company in Bethlehem and at Jerusalem 
Pharmaceutical Company in Ramallah. Proton nuclear magnetic resonance spectroscopy 
(
1
H-NMR) was done at the Hebrew University. Liquid chromatography-mass 
spectroscopy (LC-MS) was done at Al-Quds University. 
 
3.1.1.3.1. pH meter: 
 
pH meter model HM-30G: TOA electronics™ was used to measure the pH values for 
all buffers and reaction media involved in this research. 
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3.1.1.3.2. FT-IR: 
 
All infrared spectra (FTIR) were obtained from potassium bromide matrix(4000–400 
cm
-1
) using a Perkin-Elmer Precisely, Spectrum 100, FT-IR spectrometer. 
 
3.1.1.3.3. HPLC: 
 
HPLC measurements for gabapentin ProD 1 were performed using Shimadzu 
prominence HPLC-Photodiode array (PDA) system, (Shimadzu Corp. Japan). The 
HPLC system consisted of a model LC-2030C 3D equipped with a PDA. Data 
acquisition and control of the gabapentin ProD 1 were carried out using Lab solutions 
software. However, the HPLC measurements for the gabapentin ProD 2 and ProD 3 
were performed  using a Dionex HPLC system (USA). The data acquisition and control 
were performed using Chromeleon software. 
 
Analytes were separated on a 4 mm x 250 mm, 5 μm Purospher® RP-18 endcapped 
column in ProD 1 kinetic study. However, for ProD 2-3 kinetic studies, analytes were 
separated on a 4 mm x 250 mm, 5 μm particle size  C18 Phenomenex Luna® column. 
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3.1.1.3.4. 1H-NMR: 
 
All 
1
H-NMR spectra were conducted using the 500 MHz Varian NMR spectrometer. 
ProD 1-2 samples were run in deuterated methanol (CD3OD), but ProD 3 sample was 
run in deuterated dimethyl sulfoxide (DMSO-d6). For 
1
H-NMR, chemical shifts are 
reported in parts per million (ppm, δ) downfield from tetramethylsilane. Spin 
multiplicities are described as doublet (d), doublet of doublets (ddd), doublet of quartets 
(dq), doublet of triplet of doublet (dtd), singlet (s), triplet (t), quartet (q), and multiplet 
(m). Data were processed on-line at www.nmrdb.org. 
 
3.1.1.3.5. LCMS: 
 
The synthesized prodrugs were subject to LCMS analysis in the electrospray ionization 
mode (ESI) using LC-MSMS instrument of Thermo Fisher scientific at Al-Quds 
University. LC-MS analysis for both ProD 1 and ProD 3 was performed in positive 
electrospray ionization mode(+ESI). ProD 1 and ProD 3 MS conditions were as 
follows: direct injection was utilized, flow rate equals 0.05 ml/min of 20% methanol 
and 80% water and 0.1% formic acid. Full scan of 100-1200 Dalton (Da), positive ion 
voltage of 3500 volts, ion transfer tube temperature of 325
o
C, vaporizer temperature of 
275
o
C. ProD 2 analysis was carried out in negative electrospray ionization mode(-ESI). 
The mobile phase was composed of 80% water, 20% methanol, and 0.1% formic acid. 
Both full scan and product ion scan modes were performed for ProD 2. 
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 The MS conditions for full scanning mode for ProD 2 were as follows: negative ion 
voltage was 2500 volts, ion transfer tube temperature was 320
o
C, full scan range was 
between 100-400 Da, quadrupole resolution was 0.7 full width at half maximum, and 
scan rate was 1000 Da per second. Product ion scan mode conditions for ProD 2 were 
as follows: m/z scan range was between 150-400 Da, m/z precursor was 324 Da, 
quadrupole resolution was 0.7 full width at half maximum, scan rate was 1000 Da per 
second, collision energy was 15 volts, negative ion voltage was 2500 volts, ion transfer 
tube temperature was 320
o
C, and vaporizer temperature 275
o
C. 
 
3.2 Part two 
 
3.2.1.  Synthesis of gabapentin Prodrugs: 
 
Gabapentin ProD 1 preparation: In a 250 milliliter (ml) round-bottom flask, 0.85g of 
gabapentin (5 millimole (mmol)) was dissolved in 50 ml THF, 0.20 g NaOH was 
dissolved in 50 ml THF. The resulting solution was stirred for 30 minutes, then (0.715 
ml) 5 mmol of  mixture of diastereomers of  hexahydro-4-methylphthalic anhydride was 
slowly added to the reaction mixture and stirred at room temperature for 4 days. The 
reaction was monitored by thin layer chromatography which was performed on regular 
basis to check the reactions completion using chloroform and methanol (7:1) system as 
an eluent. The solvent was evaporated by the rotary evaporator and the resulting 
precipitate was washed with ethyl acetate and hexane, respectively. The white 
precipitate was dried at 37˚C. The resulting yield was 93% (Scheme 3-1). Melting point 
is 110
o
C. The product consisted of two diastereomers of ProD 1 with 89% and 11% for 
(1S, 2R) diastereomer and (1R, 2R) diastereomer of ProD 1, respectively, as revealed 
by HPLC. 
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(1S,2R) diastereomer of the ProD 1, 
1
H-NMR (500 MHz) (ppm, δ) CD3OD - 0.8797-
0.8977 (d, 3H, CH2-CH-CH3),  0.95-1.2 (m, 2H,CH2-CH2-CH), 1.4006-1.4644 (m, 5H, 
C-CH2-CH2-CH2-CH2, CH2-CH2-CH(CH3)-CH2), 1.4940-1.5395 (m, 6H, C-CH2-CH2-
CH2-CH2-CH2), 1.7649-1.810 (ddd, 2H,CH2-CH2-CH-CH2CH), 2.09-2.179 (q, 1H, NH-
C=O-CH-CH(CH2)-COOH), 2.1733 (s, 2H,C-CH2-COOH), 2.2305-2.443 ( dq, 2H, NH-
C=O-CH -CH2CH2), 3.02-3.08 (q, 1H, NH-C=O-CH(CH)-CH2), 3.2662 (s, 2H,C-
CH2NHC=O). 
 
(1R,2R) diastereomer of the ProD 1, 
1
H-NMR (500 MHz) (ppm, δ) CD3OD- 0.9474-
0.9660 (d, 3H, CH2-CH-CH3), 1.07-1.2 (m, 2H,CH2-CH2-CH), 1.4006-1.4644 (m, 5H, 
C-CH2-CH2-CH2-CH2, CH2-CH2-CH(CH3)-CH2), 1.4940-1.5395 (m, 6H,C-CH2-CH2-
CH2-CH2-CH2), 1.808-1.862 (ddd, 2H,CH2-CH2-CH-CH2CH), 2.16-2.217 (q, 1H, NH-
C=O-CH-CH(CH2)-COOH),  2.173 (s, 2H,C-CH2-COOH), 2.2305-2.443 ( dq, 2H, NH-
C=O-CH -CH2CH2), 3.08-3.14 (q, 1H, NH-C=O-CH(CH2)-CH), 3.303 (s, 2H, C-
CH2NHC=O). 
IR (KBr/νmaxcm
–1
) 1706.74 (C=O), 1646.82 (C=O), 1566.42 (C=O), 2926.55(OH), 
2863.63(OH) and 3390.08 (NH). m/z  340.19 Da [M+1]
+
. 
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Scheme ‎3-1: Gabapentin ProD 1; synthesis scheme for the formation of  two 
diastereomers of gabapentin ProD 1. 
 
Gabapentin ProD 2: We followed the same procedure for gabapentin ProD 1 but 
instead of using mixture of diastereomers of hexahydro-4-methylphthalic anhydride 
linker, cis-1,2-cyclohexanedicarboxylic anhydride was used (0.765g) 5 mmol (Scheme 
3-2). The yield was 92%. Melting point is 180
o
C.  
 
Gabapentin ProD 2, 
1
H-NMR (500 MHz) (ppm, δ) CD3OD- 1.3799-1.4253 (m, 8H, C-
CH2-CH2-CH2-CH2-CH2, CH-CH2-CH2-CH2-CH2-CH), 1.4885-1.5291 (m, 4H, C-CH2-
CH2-CH2-CH2-CH2), 1.59-1.67 (m, 2H, CH-CH2-CH2-CH2-CH2-CH), 1.7039-1.738 (m, 
2H, CH-CH2-CH2-CH2-CH2-CH), 2.08 (q, 1H, CH-CH(CH2)-COOH), 2.1026 (m, 2H, 
CH-CH2-CH2-CH2-CH2-CH), 2.26 (q, 1H, NH-C=O-CH(CH2)-CH-COOH), 2.738 (s, 
2H, C-CH2-COOH), 3.23 ( s, 2H,C-CH2-NH). 
 
IR (KBr/νmax cm
–1
) 1707.44 (C=O), 1654.94 (C=O), 1565.16 (C=O), 2926.47(OH),  
2856.88(OH) and, 3389.80(NH). m/z  324.3 Da [M-1]
-
. 
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Scheme ‎3-2: Gabapentin ProD 2; synthesis scheme for the formation of gabapentin 
ProD 2. 
 
Gabapentin ProD 3: We followed the same procedure as for gabapentin ProD 1 but 
instead of using mixture of diastereomers of hexahydro-4-methylphthalic anhydride 
linker, a mixture of diastereomers of the camphoric acid anhydride was used (0.912g) 5 
mmol (Scheme 3-3). The product yield was 93%. Melting point is 99
o
C. The product of 
ProD 3 consists of two diastereomers. With 21% and 79% for (1S,2R) diastereomer and 
(1R,2R) diastereomer of ProD 3, respectively, as revealed by HPLC.  
 
(1S,3R) diastereomer of the ProD 3, 
1
H-NMR (500 MHz) (ppm, δ) DMSO–d6 0.72 (s, 
3H, C-C-CH3), 1.2 (s, 3H, C-C-CH3), 1.29 (s, 3H, COOH-C-CH3), 1.25-1.35 (m, 2H, C-
CH2-CH2-CH2-CH2), 1.39-1.49 (m, 4H, C-CH2-CH2-CH2-CH2), 1.49-1.65 (m, 4H, C-
CH2-CH2-CH2-CH2), 1.7-1.9 (ddd, 2H, NH-C=O-CH-CH2-CH2-C), 1.9-2.09 (dtd, 2H, 
NH-C=O-CH-CH2-CH2-C), 2.1 (s, 2H,C-CH2-COOH), 2.5 (t,1H,NH-C=O-CH-CH2), 
3.25 (s, 2H, C-CH2-NH-C=O). 
36 
 
(1R,3R) diastereomer of the ProD 3, 
1
H-NMR (500 MHz) (ppm, δ) DMSO–d6 0.75 (s, 
3H, C-C-CH3), 0.95 (s, 3H, C-C-CH3), 1.12 (s, 3H, COOH-C-CH3), 1.25-1.39 (m, 2H, 
C-CH2-CH2-CH2-CH2), 139-1.49(m, 4H, C-CH2-CH2-CH2-CH2), 1.49-1.65 (m, 4H, C-
CH2-CH2-CH2-CH2), 1.7-1.9 (ddd, 2H, NH-C=O-CH-CH2-CH2-C), 1.9-2.09 (dtd, 2H, 
NH-C=O-CH-CH2-CH2-C), 2.25 (s, 2H,C-CH2-COOH), 2.56 (t, 1H, NH-C=O-CH-
CH2), 3.27 (s, 2H, C-CH2-NH-C=O). IR (KBr/νmax cm
–1
) 1760.93 (C=O), 1697.61 
(C=O), 1612.25 (C=O), 2800-3000 (OH) and 3405.95(NH). m/z 354.21 Da [M+1]
+
. 
 
 
 
Scheme ‎3-3: Gabapentin ProD 3; synthesis scheme for the formation of two 
diastereomers of gabapentin ProD 3. 
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3.3 Part three 
 
3.3.1.  Kinetic Methods: 
 
3.3.1.1. Buffer Preparation: 
 
0.1 normalized hydrochloric acid (0.1 N HCl) was prepared by diluting 8.5 ml of 
hydrochloric acid with water to 1000 ml. Moreover, pH 3 was prepared by dissolving 
6.8 g of potassium dihydrogen phosphate in 900 ml water for HPLC then it was 
adjusted by diluted orthophosphoric acid and water was added to a final volume of 1000 
ml. The same procedure was done for the preparation of buffers pH 6.8 and 7.4, 
however, the required pH was adjusted using 1N NaOH.   
 
Intraconversion of 500 ppm gabapentin ProD 1, ProD 2, and ProD 3 solutions, in 0.1N 
HCl and buffers with pHs of 3, 6.8 and 7.4, to gabapentin was followed by HPLC at a 
wavelength of 210 nanometers. This wavelength was selected since the prodrugs lack 
absorption at higher lambda. Hydrolysis reactions were run mostly at 37˚C. 
 
3.3.1.2. Calibration curves: 
3.3.1.2.1. Calibration curve for ProD 1: 
 
A 50 mg of gabapentin ProD 1 was dissolved in 100 ml methanol in order to prepare a 
stock solution with a concentration of 500 ppm. Subsequently, diluted solutions with the 
following concentrations (31.25, 62.5, 125, 250 and 500 ppm) were prepared from the 
stock.  
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20 μl of each solution was injected into the HPLC and all the peaks were recorded using 
the following HPLC conditions: 4 mm x 250 mm, 5 μm Purospher® RP-18 endcapped 
column, a mobile phase of 75% (5.28g (NH4)2 HPO4 to 1000 ml with purified water and 
then pH was adjusted to 6.5 with orthophosphoric acid), 10% methanol and 15% 
Acetonitrile, a flow rate of 1 ml minute
-1
 and ultraviolet  detection at a wavelength of 
210 nanometers.   
Peak area vs. concentration curves for gabapentin ProD 1 was then plotted, and a 
coefficient of determination (R
2
) of the plot was calculated.  
 
3.3.1.2.2. Calibration curve for ProD 2: 
 
A 50 mg of gabapentin ProD 2 was dissolved in 100 ml methanol in order to prepare a 
stock solution with a concentration of 500 ppm. Subsequently, diluted solutions with the 
following concentrations (31.25, 62.5, 125, 250 and 500 ppm) were prepared from the 
stock. 20 μl of each solution was injected into the HPLC and the peak for the 
pharmaceuticals was recorded using the following HPLC conditions: 4 mm x 250 mm, 
5 μm phenomenex Luna® RP-18 end-capped column using mobile phase contains: 80% 
(5.28g (NH4)2HPO4 to 1000 ml with purified water and then pH was adjusted to 6.5 
with orthophosphoric acid), 10% methanol and 10% acetonitrile, a flow rate of 1 ml 
minute
-1
 and ultraviolet detection at a wavelength of 210 nanometers. 
 
Peak area vs. concentration curve for  gabapentin ProD 2 was then plotted, and R
2
 of 
the plot was calculated. 
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3.3.1.2.3. Calibration curve for ProD 3: 
 
A 50 mg of gabapentin ProD 3 was dissolved in 100 ml methanol in order to prepare a 
stock solution with a concentration of 500 ppm. Subsequently, diluted solutions with the 
following concentrations (31.25, 62.5, 125, 250 and 500 ppm) were prepared from the 
stock. 20 μl of each solution was injected into the HPLC and the peak for the 
pharmaceuticals was recorded using the following HPLC conditions: 4 mm x 250 mm, 
5 μm phenomenex Luna® RP-18 end-capped column using mobile phase contains: 77% 
(5.28g (NH4)2HPO4 to 1000 ml with purified water and then pH was adjusted to 6.5 
with orthophosphoric acid), 10% methanol and 13% acetonitrile, a flow rate of 1 ml 
minute
-1
 and ultraviolet detection at a wavelength of 210 nanometers.   
Peak area vs. concentration curve was then plotted, and R
2
 of the plot was calculated. 
 
3.3.1.3. Preparation of gabapentin standard and sample solution: 
 
A 500 ppm of gabapentin standard was prepared by dissolving 50 mg of gabapentin in 
100 ml of 0.1N hydrochloric acid (HCl), buffer pH 3, buffer pH 6.8 and buffer pH 7.4, 
then each sample was injected into HPLC to detect the retention time of gabapentin. 
 
A 500 ppm of the linkers standard (mixture of diastereomers of hexahydro-4-
methylphthalic anhydride, cis-1,2-cyclohexanedicarboxylic anhydride, and mixture of 
diastereomers of camphoric acid anhydride) was prepared by dissolving 50 mg of each 
linker in 100 ml of 0.1N HCl, buffer pH 3, buffer pH 6.8 and buffer pH 7.4, then each 
sample was injected into HPLC to detect the retention time of the linkers. 
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A 500 ppm of each gabapentin ProD 1-3 was prepared by dissolving 50 mg of the 
gabapentin ProD 1-3 in 100 ml of 0.1N HCl, buffer pH 3, buffer pH 6.8 or buffer pH 
7.4 then each sample was injected into HPLC to detect the retention time. The 
progression of the reactions was followed by monitoring the disappearance of the 
prodrugs and appearance of gabapentin and the linkers attached versus time. 
 
Gabapentin ProD 1-3 were incubated at 37˚C to be monitored on the HPLC for several 
days to detect the intraconversion of the three prodrugs to their corresponding parent 
drug, to calculate the t½ of each prodrug. 
 
3.4 Part Four 
 
3.4.1.  In silico prediction of physicochemical parameters, drug-likeness, ADMET 
for the synthesized gabapentin ProD 1-3: 
 
In silico prediction approaches increase our ability to predict physicochemical, 
pharmacokinetic, metabolic, and toxicity properties of drugs at the preclinical stage, 
thereby accelerating the drug discovery process and reducing the associated time, costs, 
and animal experiments [159].  
 
Three software were used in this study to predict the physicochemical properties and 
number of ADMET values for the synthesized gabapentin prodrugs. ADMET are 
considered as the main reason for the failure of drug candidates at the later phases of 
drug development [159]. The first one is ACD/Lab software, version: v12.1, that can 
predict physicochemical, ADME, and toxicity features from the structure of the 
compound [160].  
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The second one is an online web server, Chemicalize, which was developed and is 
owned by ChemAxon and provides many cheminformatics tools to predict many 
physicochemical properties for the chemical compound [161]. The third software is 
preADME version 2.0; an online platform for predicting drug-likeness properties, 
ADME data, and toxicity of the chemical structure [162, 163]. Then by using Lipinski‘s 
rule of five, we assessed the drug-likeness and determined if these compounds will be 
orally active substances in human [164]. 
 
3.4.2.   In silico  prediction of BBB permeability of the synthesized gabapentin 
ProD 1-3: 
 
Predicting BBB permeability is very significant to the development of drugs that target 
CNS; since a molecule must pass this barrier in order to display a pharmacological 
activity in the brain [165]. In silico BBB permeability was predicted for gabapentin 
ProD 1-3 by utilizing an online program at http://www.cbligand.org/BBB/ [166]. This 
uses AdaBoost and supports vector machine (SVM) combining 4 diverse fingerprints to 
expect if a compound can enter through the BBB (BBB+) or cannot enter through the 
BBB (BBB-) [166]. 
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Chapter Four 
 
4. Results and Discussion: 
 
Three gabapentin prodrugs were proposed to synthesize utilizing three different linkers. 
As indicated above in Schemes 3-1 to 3-3, these gabapentin prodrugs are composed of a 
promoiety containing a carboxylic acid group (hydrophilic moiety) and the rest of the 
prodrug molecule (a lipophilic moiety). The combination of both, the hydrophilic and 
lipophilic groups, provides a prodrug entity with potential to have high permeability (a 
modified HLB).Therefore; these prodrugs will be expected to be absorbed by passive 
diffusion to provide higher and dose-independent bioavailability. We have successfully 
synthesized these proposed gabapentin prodrugs with three various linkers. They were 
characterized by melting points, FT-IR, 
1
H-NMR, and LC-MS analytical techniques, to 
guarantee pure gabapentin prodrugs. 
 
ProD 1 and ProD 3 linkers consist of a mixture of diastereomers and produced 
prodrugs with two diastereomers. ProD 1 diastereomers were 89% (1S, 1R) and 11% 
(1R,2R), while, ProD 3 had diastereomers with 21% and 79% for (1S, 3R) and (1R, 
3R), respectively. In contrast, the linker of ProD 2 was cis isomer and therefore 
produced cis isomer of the prodrug. 
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4.1 Gabapentin standard and prodrugs characterization using different analytical 
techniques 
 
 
4.1.1.  Melting point, FT-IR, 1H-NMR and LC-MS analysis of gabapentin 
standard: 
 
1) The melting point of gabapentin is 167-169˚C.  
2) FT-IR (KBr/νmax cm
–1
) 1614.82 cm-1 (C=O stretch of carboxylic acid), 2930.55 cm-1 
and 2856  cm-1  (CH stretching) (Figure 4-1). 
3) 
1
H-NMR (500 MHz) (ppm, δ) CD3OD- 1.39-1.59 (m, 10 H, C-CH2-CH2-CH2-CH2-
CH2), 2.45 (s, 2H, C-CH2-COOH), 2.9 (s, 2H, C-CH2-NH2) (Figure 4-2). 
4) Gabapentin molecular formula is C9H17NO2. LC-MS (+ESI) m/z 172.15 Da [M+1]
+
 
(Figure 4-3). 
 
 
 
 
Figure ‎4-1: FT-IR spectrum of gabapentin. 
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Figure ‎4-2: 1H-NMR spectrum of gabapentin. 
 
 
 
 
 
Figure ‎4-3: +ESI-LC-MS spectrum of gabapentin. 
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4.1.2.  Melting point, FT-IR, 1H-NMR and LC-MS analysis of gabapentin ProD 1: 
 
1) The melting point of ProD 1 is 110 ˚C.  
2) FT-IR (KBr/νmaxcm
–1
) 1706.74 (C=O of the carboxylic acid), 1646.82 (C=O of the 
amide), 1566.42 (N-H bending of the amide), 2926.55 (C-H stretching), 2863.63 (C-H 
stretching) and 3399.08 (NH) (Figure 4-4). 
3) 
1
H-NMR (500 MHz) (ppm, δ) of the (1S,2R) diastereomer of ProD 1 CD3OD- 
0.8797-0.8977 (d, 3H, CH2-CH-CH3), 0.95-1.07 (m, 2H, CH2-CH2-CH), 1.4006-1.4644 
(m, 5H, C-CH2-CH2-CH2-CH2, CH2-CH2-CH(CH3)-CH2), 1.4940-1.5395 (m, 6H, C-
CH2-CH2-CH2-CH2-CH2), 1.7649-1.810 (ddd, 2H,CH2-CH2-CH(CH3)-CH2CH), 2.09-
2.179 (q,1H, NH-C=O-CH-CH(CH2)-COOH), 2.1733 (s, 2H, C-CH2-COOH), 2.2305-
2.443 (dq, 2H, NH-C=O-CH-CH2CH2), 3.02-3.08 (q, 1H, NH-C=O-CH(CH)-CH2), 
3.2662 (s, 2H, C-CH2NHC=O) (Figure 4-5).  
1
H-NMR (500 MHz) (ppm, δ) of the (1R,2R) diastereomer of ProD 1 CD3OD- 0.9474-
0.9660 (d, 3H, CH2-CH-CH3),  1.07-1.2 (m, 2H, CH2-CH2-CH), 1.4006-1.4644 (m, 5H, 
C-CH2-CH2-CH2-CH2, CH2-CH2-CH(CH3)-CH2), 1.4940-1.5395 (m, 6H, C-CH2-CH2-
CH2-CH2-CH2), 1.808-1.862 (ddd, 2H, CH2-CH2-CH(CH3)-CH2CH), 2.16-2.217 (q, 1H, 
NH-C=O-CH-CH(CH2)-COOH), 2.173 (s, 2H,C-CH2-COOH), 2.2305-2.443 (dq, 2H, 
NH-C=O-CH-CH2CH2), 3.08-3.14 (q, 1H, NH-C=O-CH(CH2)-CH), 3.303 (s, 2H, C-
CH2NHC=O) (Figure 4-5). The purity of the compound calculated from NMR is 93.8%. 
4) The product molecular formula is C18H29NO5 (yield 93%). 
5) LC-MS (+ESI mode) m/z 340.19 Da [M+H]
+
: the molecular mass of  ProD 1 is 339.4 
Da. The positive electrospray ionization gave the protonated [M+H]
 +
 at m/z of 340.19 
Da. Sodiated adduct peak appeared at m/z of 362.18 Da advocating the [M+ Na]
+
 ion 
existence (Figure 4-6). 
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Figure ‎4-4:  FT-IR spectrum of ProD 1. 
 
 
 
 
Figure ‎4-5: 1H-NMR spectrum of ProD 1 in CD3OD. 
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Figure ‎4-6: +ESI- LC-MS spectrum of ProD 1. 
 
 
4.1.3.  Melting point, FT-IR, 1H-NMR and LC-MS analysis of gabapentin ProD 2: 
1) The melting point of ProD 2 was 180 ˚C.  
2) FT-IR (KBr/νmax cm–1) 1707.44 (C=O of the carboxylic acid), 1654.94 (C=O of the 
amide),  1565.16 (N-H bending of the amide), 2926.47 (C-H stretching), 2856.88 (C-H 
stretching) and  3389.80 (NH) (Figure 4-7). 
3) 
1
H-NMR (500 MHz) (ppm, δ) CD3OD- 1.3799-1.4253 (m, 8H, C-CH2-CH2-CH2-
CH2-CH2, CH-CH2-CH2-CH2-CH2-CH), 1.4885-1.5291 (m, 4H, C-CH2-CH2-CH2-CH2-
CH2), 1.59-1.67 (m, 2H, CH-CH2-CH2-CH2-CH2-CH), 1.7039-1.738 (m, 2H, CH-CH2-
CH2-CH2-CH2-CH), 2.08 (q, 1H, CH-CH(CH2)-COOH), 2.1026 (m, 2H, CH-CH2-CH2-
CH2-CH2-CH), 2.26 (q, 1H, NH-C=O-CH(CH2)-CH-COOH), 2.738 (s, 2H, C-CH2-
COOH), 3.23 ( s, 2H, C-CH2-NH) (Figure 4-8). The purity of the compound calculated 
from NMR is 92.7 %.  
4) The product molecular formula is C17H27NO5 (yield 92%). 
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5) LC-MS (-ESI mode) m/z 324.3 Da [M-H]
-
 and LC-MSMS of product ion scan 
respectively (Figure 4-9 and 4-10). 
 
 
 
 
Figure ‎4-7: FT-IR spectrum of ProD 2. 
 
 
 
 
 
Figure ‎4-8: 1H-NMR spectrum of ProD 2 in CD3OD. 
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Figure ‎4-9: -ESI-LC-MS spectrum of ProD 2 (Full scan mode). 
 
 
 
 
 
Figure ‎4-10: -ESI- LC-MSMS spectrum of ProD 2 (Product ion scan mode). 
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4.1.4. Melting point, FT-IR, 1H-NMR and LC-MS analysis of gabapentin ProD 3: 
 
1) The melting point of ProD 3 was 99 ˚C.  
2) IR (KBr/νmax cm
–1
) 1760.93 (C=O of the carboxylic acid), 1697.61 (C=O of the 
amide), 1612.25 (N-H bending of the amide), 2800-3000 (C-H stretching) and 3405.95 
(NH) (Figure 4-11). 
3) 
1
H-NMR (500 MHz) (ppm, δ) for the (1S,3R) diastereomer of the ProD 3 (DMSO–
d6)  0.72 (s, 3H, C-C-CH3), 0.95 (s, 3H, C-C-CH3), 1.12 (s, 3H, COOH-C-CH3), 1.25-
1.35 (m, 2H, C-CH2-CH2-CH2-CH2), 1.39-1.49 (m, 4H, C-CH2-CH2-CH2-CH2), 1.49-
1.65 (m, 4H, C-CH2-CH2-CH2-CH2), 1.7-1.9 (ddd, 2H, NH-C=O-CH-CH2-CH2-C), 1.9-
2.09 (dtd, 2H, NH-C=O-CH(C)-CH2-CH2-C), 2.1 (s, 2H,C-CH2-COOH), 2.5 (t, 1H, 
NH-C=O-CH(C)-CH2), 3.25 (s, 2H, C-CH2-NH-C=O)  (Figure 4-12). 
1
H-NMR (500 MHz) (ppm, δ) for the (1R,3R) diastereomer of the ProD 3 (DMSO-d6) 
–0.75 (s, 3H, C-C-CH3), 1.2 (s, 3H, C-C-CH3), 1.29 (s, 3H, COOH-C-CH3), 1.25-1.39 
(m, 2H, C-CH2-CH2-CH2-CH2), 1.39-1.49 (m, 4H, C-CH2-CH2-CH2-CH2), 1.49-1.65 
(m, 4H, C-CH2-CH2-CH2-CH2), 1.7-1.9 (ddd, 2H, NH-C=O-CH-CH2-CH2-C), 1.9-2.09 
(dtd, 2H, NH-C=O-CH-CH2-CH2-C), 2.25 (s, 2H, C-CH2-COOH), 2.56 (t, 1H, NH-
C=O-CH-CH2), 3.27 (s, 2H, C-CH2-NH-C=O) (Figure 4-12). Peak appeared at 3.45 is 
due to the amount of water present in DMSO, as DMSO is highly miscible with water, 
during handling DMSO absorbs moisture and the broad peak at 3.45 is most likely due 
to the moisture present. 
4) The product molecular formula is C19H31NO5 (yield 93%). 
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5) LC-MS (positive mode) m/z 354.21 Da [M+1]
+
: the molecular mass of the ProD 3 is 
353.25 Da. The positive electrospray ionization gave the protonated [M+H]
+
 at m/z of 
354.21 Da. Sodiated adduct peak appeared at m/z of 376.20 Da advocating the [M+ 
Na]
+
 ion existence (Figure 4-13). 
   
 
 
Figure ‎4-11: FT-IR spectrum of ProD 3. 
 
 
 
 
 
Figure ‎4-12: 1H-NMR spectrum of ProD 3 in CD3SOCD3. 
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Figure ‎4-13: LC-MS sprctrum of ProD 3. 
 
 
 
4.2 Hydrolysis studies 
 
Hydrolysis of gabapentin prodrugs was investigated using HPLC. Peaks of standards 
and degradation products were monitored to determine the rate of cleavage of the three 
synthesized gabapentin prodrugs. Kinetic studies were performed at constant 
temperature (37
o
C) and at different pH in buffers such as 0.1N HCl, pH 3, pH 6.8, and 
pH 7.4 which resemble the physiological environments in the human body. The 0.1N 
HCl and pH 3 were chosen to study the intraconversion of the gabapentin prodrugs in 
pH as of the stomach because the mean stomach pH of the adult is approximately 1-3, 
whereas, buffer pH 6.8 represents the small intestine pathway.  pH 7.4 was selected to 
study the intraconversion of the tested prodrugs in pH as of the blood circulation 
system.  
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Calibration curves were obtained by plotting peak area of the prodrugs versus 
concentration. As shown in Figure 4-14, excellent linearity with R
2
 of 0.997 for  
gabapentin ProD 1 and 0.999 for both gabapentin ProD 2 and ProD 3 were obtained.  
 
 
 
 
Figure ‎4-14: Calibration curves of ProD 1 (a), ProD 2 (b), and ProD 3 (c). 
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4.2.1.  In vitro intraconversion of gabapentin ProD 1-3  to their parent drug: 
 
The hydrolysis kinetic studies of gabapentin ProD 1-3 were done in aqueous buffers in 
the same method to that carried out by Kirby et al. on maleamic acids 1-9 (Figure 2-4) 
[167]. This is to explore if the gabapentin prodrugs undergo hydrolysis in an aqueous 
medium and measure the rate of the hydrolysis should it occur, indicating the fate of the 
prodrugs in the system. The kinetics of the acid-catalyzed hydrolysis of the synthesized 
gabapentin ProD 1-3 were conducted in four different aqueous media: 0.1 N HCl, 
buffer pH 3, buffer pH 6.8 and buffer pH 7.4. The results and chromatograms of the 
kinetic study are summarized in Figures 4-15 to 4-27.  
 
Under experimental conditions, ProD 1-2 were hydrolyzed to liberate the parent drug, 
gabapentin, as demonstrated by HPLC analysis (Figures 4-15 to 4-25). At constant 
temperature and pH, the reactions display strict first-order kinetics as an observed rate 
constants of  hydrolysis (kobs) were markedly constant and straight lines were acquired 
by plotting ln concentration of residual prodrugs versus time (Figures 4-28 to 4-29), 
whereas the gabapentin ProD 3 was shown to be extremely stable at constant pH and 
temperature as evident by HPLC analysis indicated in Figure 4-26 to 4-27.  
 
ProD 1 HPLC conditions gave good resolution between the two ProD 1 diastereomeric 
peaks (resolution (Rs) > 2.5) as depicted in Figure 4-16 to 4-19. However, improper 
separation (Rs < 1.2) between the two diastereomer peaks of ProD 3 was observed by 
using ProD 3 HPLC conditions (Figure 4-27). Both ProD 3 diastereomers were shown 
to be very stable. Thus, improving the resolution between ProD 3 diastereomers will 
only consume time and money. 
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The kobs and the corresponding t½ for gabapentin prodrugs in different media were 
estimated from the linear regression equation correlating the ln concentration of the 
residual prodrug versus time (Tables 4-1 to 4-3). 
 
Acid-catalyzed hydrolysis of the gabapentin ProD 1-2 was found to be much higher at 
0.1N HCl and pH 3 (acidic media) than pH 6.8 and pH 7.4 (Figures 4-15 to 4-25). 
Gabapentin ProD 1 experimental half-life values in 0.1N HCl, buffer pH‘s 3, 6.8 and 
7.4 were 16.57, 17.76, 101.91, and 119.48 hrs, respectively. ProD 2 was hydrolyzed 
into its parent drug in 0.1N HCl, buffer pH‘s 3, 6.8, and 7.4 with experimental half-life 
values of 20.3, 22.70, 130.75 and 277.2 hrs, respectively. 
 
At pH 5.0–7.4, intestine environment and blood circulation, the carboxylic group in 
ProD 1 and ProD 2 will equilibrate with the related carboxylate form. Consequently, 
the free acid form will undergo proton transfer reaction after being transferred by the 
membrane to release gabapentin. The synthesized gabapentin ProD 1-2 will be designed 
for oral use in the form of enteric coated tablets. Enteric coated tablets are completely 
stable at high acidic pH found in the stomach, but dissolve quickly at less acidic pH. For 
instance, enteric coated tablets will not dissolve in the acidic juices of the stomach (pH 
~3), but they will at higher pH (above pH 5.5)  in the small intestine. In the intestine, 
prodrugs ProD 1-2 will present in the ionic and acidic forms where the equilibrium 
constant for the exchange between both forms is dependent on the pKa of the given 
prodrug. 
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The pKa's of gabapentin ProD 1-2 are in the range of 5-6 because experimentally 
determined pKa's for ProD 1-2 linkers are in the range of 5.0-6.0. Therefore, it is 
predicted that the pKa's of the related prodrugs will be in the same range.  
Thus, we predict that at pH 6.8 and pH 7.4 the ratio of the free acid form that undergoes 
acid-catalyzed hydrolysis will be comparatively low and the anionic form of the 
prodrugs will be dominant. At 0.1N HCl and pH 3, most of the prodrug will present as 
the free acid form. This interpreted the differences in rates at the different pH buffers. 
 
Thus, both gabapentin ProD 1-2 will release active drug in a sustained release manner 
as indicated by their t½, but immediate release of drug from prodrug will be achieved 
by using carboxylic linkers having pKa close to that of the blood circulation (pH 7.4). 
 
On the other hand, ProD 1 was found to have a higher hydrolysis rate than ProD 2, this 
is due to a structural feature of 4-methylcyclohexane moiety of the ProD 1 linker, 
which contains a methyl group on the cyclohexane (strained system) which results in a 
decrease of the distance between the two reactive centers (hydroxyl oxygen of the 
carboxylic group and the amide carbonyl carbon). Hence, the hydrolysis of gabapentin 
ProD 1 is faster than that of gabapentin ProD 2. 
 
However, the linker of gabapentin ProD 3 has the lowest pKa, which is about 4. Thus, 
it is predictable that the pKa of the ProD 3 will be about 4. Therefore, most of ProD 3 
will exist as the anionic form at pH 6.8 and pH 7.4. This explains why ProD 3 was 
completely stable and no liberation of gabapentin was observed in both buffers. In 
addition, ProD 3 was extremely insoluble in the acidic buffers of 0.1N HCl and pH 3. 
Thus, no reaction happened in the acidic environment for this prodrug 
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Figure ‎4-15: Chromatograms showing gabapentin standard (a) and both linker 1 
diastereomers (b) at gabapentin ProD 1 HPLC conditions. 
 
59 
 
 
 
 
 
Figure ‎4-16: Chromatograms showing the intraconversion of  ProD 1 at 0.1 N HCl 
after 15 min (a) and after 72 hrs (b). 
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Figure ‎4-17: Chromatograms showing the intraconversion of  ProD 1 at pH 3 after 9 
hrs (a) and at end of the reaction (b). 
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Figure ‎4-18: Chromatograms showing the intraconversion of ProD 1 at pH 6.8 after 
24 hrs (a) and after 240 hrs (b). 
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Figure ‎4-19: Chromatograms showing the intraconversion of ProD 1 at pH 7.4 after 30 
hrs (a) and after 240 hrs (b). 
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Figure ‎4-20: Chromatograms showing gabapentin standard at gabapentin ProD 2 
HPLC conditions. 
 
 
 
 
 
Figure ‎4-21: Chromatograms showing linker 2 standard at pH 0.1N HCl and pH 3 (a) 
and pH 6.8 and 7.4 (b) at gabapentin ProD 2 HPLC conditions. 
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Figure ‎4-22: Chromatograms showing the intraconversion of ProD 2 at pH 0.1 N HCl 
after 1 hr (a), and after 73 hrs (b). 
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Figure ‎4-23: Chromatograms showing the intraconversion of ProD 2 at pH 3 after 2 hrs 
(a) and after 79 hrs (b). 
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Figure ‎4-24: Chromatograms showing the intraconversion of  ProD 2 at pH 6.8 after 1 
hr (a) and after 380 hrs (b). 
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Figure ‎4-25: Chromatograms showing the intraconversion of ProD 2 at pH 7.4 after 5 
hrs (a) and after 355 hrs (b). 
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Figure ‎4-26: Chromatograms showing gabapentin standard (a) and both linker 3 
diastereomers (b) at gabapentin ProD 3 HPLC conditions. 
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Figure ‎4-27: Chromatograms showing the stability of ProD 3 at pH 7.4 after 1 hr (a) 
and after 168 hrs (b). 
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Figure ‎4-28: First order hydrolysis plot for both diastereomers of ProD 1 in 0.1N HCL 
(a), buffer pH 3 (b), buffer pH 6.8 (c), and buffer pH 7.4 (d). 
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Figure ‎4-29: First order hydrolysis plot for ProD 2 in 0.1N HCl (a), buffer pH 3 (b), 
buffer pH 6.8 (c), and buffer pH 7.4 (d). 
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Table ‎4-1: The kobs value and t½ for the intraconversion of ProD 1 in 0.1N HCl, pH 3, 
pH 6.8, and pH 7.4. 
 
Medium kobs(hr
-1
) t½ (hr) 
0.1N HCl 0.0418 16.57 
Buffer pH 3 0.039 17.76 
Buffer pH 6.8 0.0068 101.91 
Buffer pH 7.4 0.0058 119.48 
 
 
 
Table ‎4-2: The kobs value and t½ for the intraconversion of ProD 2 in 0.1N HCl, pH 3, 
pH 6.8, and pH 7.4. 
 
Medium kobs (hr
-1
) t½ (hr) 
0.1N HCl 0.0340 20.3 
Buffer pH 3 0.0304 22.79 
Buffer pH 6.8 0.0053 130.75 
Buffer pH 7.4 0.0025 277.2 
 
 
 
Table ‎4-3: The kobs value and t½ for the intraconversion of ProD 3 in 0.1N HCl, pH 3, 
pH 6.8, and pH 7.4. 
 
Medium kobs(hr
-1
) t½ (hr) 
0.1N HCl No reaction ------ 
Buffer pH 3 No reaction ------ 
Buffer pH 6.8 No reaction ------ 
Buffer pH 7.4 No reaction ------ 
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4.3 In silico prediction of physicochemical parameters, drug-likeness and CNS like 
properties for gabapentin ProD 1-3 
 
4.3.1.  Drug-likeness: 
 
The physicochemical properties of more than 2,000 biologically active compounds were 
evaluated by Lipinski et al. and subsequently what is known as ―Lipinski‘s rule of five‖ 
was conceived [168]. They concluded that ninety percent of orally active drugs that 
have successfully reached phase II clinical studies were associated with four 
physicochemical parameter ranges: (molecular weight < 500, partition coefficient (log 
P) < 5, H-bond donors < 5 and H-bond acceptors < 10), but it applies only to passive 
absorption. Thus, compounds that comply with these physicochemical properties, are 
predicted to be more membrane permeable and have drug-like properties [168,169]. 
Later, the ranges of some parameters were specified and other criteria added to the rule 
in order to enhance the prediction of drug-likeness. Such ranges include log P −0.4 to 
+5.6, molecular weight 180 to 500 Da, molar refractivity 40 to 130, and a total number 
of atoms ranging 20 to 70 [170]. According to the values of physicochemical properties 
of the synthesized gabapentin prodrugs, all the synthesized prodrugs obey Lipinski‘s 
rule of five and have drug-like properties (Table 4-4). 
 
Moreover, Veber et al. suggested that compounds which meet only the two criteria of 
polar surface area equal to or less than 140 Å
2 
and has 10 or fewer rotatable bonds are 
predicted to have high oral bioavailability [171]. All synthesized gabapentin prodrugs in 
this study meet these criteria (Table 4-4). 
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4.3.2.  Molecular lipophilicity: 
 
Lipophilicity is a significant molecular feature in medicinal chemistry and also in 
rationalized drug development and design. It affects the physiochemical properties of 
compounds such as permeability, toxicity, and bioavailability [172].  
 
The n-octanol/water partition coefficient has been used to quantify lipophilicity of 
compounds for many years [173]. This coefficient is frequently defined as log P, which 
is the ratio of the unionized compound concentration in 1-octanol to its concentration in 
water. Thus this coefficient is a measure of differential solubility of the compound 
between these two solvents [173]. Hansch and Fujita developed the first method for log 
P calculation [174] and now several computational methods, including in silico tools, 
have been designed in order to predict log P value. Lipinski states that a compound is 
more likely to have good absorption or permeability when the calculated log P is < 5 
[164]. In addition, Hitchcock et al. Suggested a range of  2-5 for calculated log P in 
order to increase the potential for BBB penetration [175]. Results of calculated log P 
values using Chemicalize software showed that all values of the log P for the 
synthesized gabapentin prodrugs were within these limits (Table 4-4). 
 
4.3.3.  Distribution coefficient (log D): 
 
Log D is a pH-dependent version of log P that takes into account the difference in 
lipophilicity of a drug in regard to the ionic states present at key biological pH values 
[176,177].  
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Since about 95% of all drugs are ionizable, it was suggested that log D is a better 
descriptor for the lipophilicity of chemical compounds in physiological systems. Thus, 
Bhal et al. proposed that Log P should be replaced with Log D in ‗drug-likeness filters‘ 
such as the rule of five [177]. Moreover, Van de Waterbeemd et al. demonstrated that, 
of a total of 125 compounds, all those acting in the CNS are within the ranges of 1 ≤ log 
D (pH 7.5) ≤ 4 [178]. Chemicalize software was used for the calculation of log D values 
of the synthesized gabapentin prodrugs. Results showed that all synthesized gabapentin 
prodrugs were within this range (Table 4-1). 
 
4.3.4.  Aqueous solubility (log S): 
 
Solubility is a common and challenging physicochemical parameter for drug discovery. 
The aqueous solubility of a drug is essential as it considerably affects its absorption and 
distribution characteristics. Generally, a low soluble drug is avoidable because it 
frequently has poor absorption. In 2010, Alelyunas et al. showed that the aqueous 
solubility at pH 7.4 is a significant prerequisite for a CNS targeted drug [179]. All the 
synthesized gabapentin prodrugs were predicted by Chemicalize program to be highly 
soluble at pH 6.8 and 7.4. However, ProD 3 has poor solubility at pH 3 and 0.1 N HCl 
(Table 4-2). 
4.3.5.  In silico prediction of BBB permeability and log BB:  
 
Designing drugs that can penetrate the BBB and have an adequate concentration at the 
desired therapeutic target in the CNS is a significant challenge for medicinal chemists 
working in CNS drug development [180]. 
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BBB permeability software predicted that gabapentin ProD 1-3 have the capability to 
pass the BBB. Abraham et al. suggested that compounds with log BB less than -1.0 will 
not cross through the BBB, while compounds with log BB equal to or more than -1.0 
are predicted to enter to CNS [180]. All the synthesized gabapentin prodrugs were 
predicted to have log BB ≥ -1. 
 
Table ‎4-4: Physiochemical properties and drug-likeness of the gabapentin and its 
synthesized prodrugs. 
 
Physiochemical 
properties 
Drug-like 
criteria 
Gabapentin ProD 1 ProD 2 ProD 3 
 
Molecular 
weight 
 
< 500 171.23 339.43 325.4 353.45 
 
No. of 
Hydrogen 
Bond Donors 
 
< 5 2 3 3 3 
 
No. of 
Hydrogen 
Bond 
Acceptors 
 
< 10 3 6 6 6 
 
log P 
 
< 5 -1.9 2.527 2.326 2.983 
 
log D at pH 7.4 
 
-1  ≤ log D (pH 
7.4) ≤ 3 
-1.25 1.279 1.078 1.734 
 
TPSA 
 
<140 Angstrom   
  
(Ǻ2) 
63.32 Ǻ2 103.7 Ǻ2 103.7 Ǻ2 103.7 Ǻ2 
 
Molar 
Refractivity 
 
40 to 130 cm
3
 46.33 cm3 87.76 cm3 83.05 cm3 92.37 cm3 
 
No. of 
Rotatable 
Bonds 
 
≤10 3 6 6 6 
 
Total number 
of atoms 
 
20 to 70 22 33 50 35 
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Table ‎4-5: CNS like properties for gabapentin and its synthesized prodrugs.  
 
 
Physiochemic
al properties. 
CNS-like 
criteria 
Gabapentin ProD1 ProD2 ProD3 
 
log BB 
 
Log BB ≥ -1 
[180].  
-0.19 -0.704 -0.89 -1 
 
Molecular 
weight 
 
MW < 450 
[181,182]. 
171.25 339.43 325.4 353.45 
 
log P 
 
2-5 [175]. -1.9 2.527 2.326 2.983  
 
log D at pH 
7.4 
 
1  ≤ log D (pH 
7.4) ≤ 4 [181]. 
-1.25 1.279 1.078 1.734 
 
Log S 
 
-4 < log S < 0 
[182]. 
-1.6 -3.499 
 
-3.125 
 
-3.769 
  
 
 
 
 
Figure ‎4-30: BBB permeability prediction for ProD 1 (a), ProD 2 (b), and ProD 3 (c). 
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4.4 In silico ADMET prediction 
 
In silico pharmacokinetic properties and toxicity were studied using PreADME software 
for all three gabapentin prodrugs. The results of the pharmacokinetic and toxicity 
predictions (Table 4-6) showed that all the prodrugs showed good pharmacokinetic 
properties. For example, Yee et al. suggested that compound with human intestinal 
absorption (HIA) more than 70 will be classified as a well-absorbed compound and 
compound with colorectal adenocarcinoma cell lines (caco2) value more than 4 will be 
absorbed by the intestine [183]. All synthesized gabapentin prodrugs predicted to have 
HIA values more than 70 and caco2 values more than 4 (Table 4-6). Furthermore, the 
synthesized gabapentin prodrugs are predicted to be non-inhibitors for the CYP 
enzymes or P-glycoprotein (Pgp), which means to have less drug-drug interactions 
[101,184] (Table 4-6). In addition, none of the prodrugs had a high risk of toxicity or 
mutagenicity. 
 
Table ‎4-6: ADMET prediction for ProD 1 (a), ProD 2 (b), and ProD 3 (c). 
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Chapter Five 
 
5.  Conclusion and Future direction 
 
5.1 Conclusion 
 
Gabapentin has pharmacokinetic limitations which limit its clinical effectiveness. For 
example, it has dose-dependent bioavailability. Consequently, there is need to 
synthesize prodrugs of gabapentin that have the potential for higher and more 
predictable bioavailability than the current medications when given in different dosage 
forms. Moreover, they should have the ability to hydrolyze to gabapentin via 
intramolecular reaction and without any need for enzyme catalysis. 
 
Based on Kirby`s enzyme model (Proton transfer in N-alkylmaleamic acids), three 
different gabapentin prodrugs were synthesized and characterized. These prodrugs have 
a carboxylic group as a hydrophilic moiety and the rest of the prodrug as a lipophilic 
moiety, where the combination of  both moieties secures a modified HLB. Thus, the 
synthesized gabapentin prodrugs were expected to have predictable and enhanced 
bioavailability in comparison to gabapentin as a result of improving its passive 
transport. Moreover, the synthesized prodrugs can be used in many dosage forms such 
as enteric coated tablets. In vitro intraconversion of these prodrugs to their parent drug, 
gabapentin, showed that t½ was highly affected by the pH of the medium, the pKa of 
the linker, and the distance between the two reactive centers. Gabapentin ProD 1 was 
readily hydrolyzed in 0.1N HCl, buffer pH 3, buffer pH 6.8, and buffer pH 7.4 with 
experimental t½ values of 16.57 hrs, 17.76 hrs, 101.91 hrs and 191.48 hrs, respectively. 
The experimental t½ values for gabapentin ProD 2 in 0.1N HCl and pH 3, pH 6.8 and 
pH 7.4 were 20.3 hrs, 22.79 hrs, 130.75 hrs and 277.2 hrs, respectively. 
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However, ProD 3 was extremely insoluble in 0.1 N HCl and pH 3. Moreover, it was 
found to be completely stable at pH 6.8 and pH 7.4 and no reaction was observed. This 
is due to the comparatively low pKa of its linker. 
 
In silico prediction of the pharmacokinetic and toxicity parameters of the synthesized 
gabapentin prodrugs found that all have favorable pharmacokinetic features, drug-like, 
and have a low risk of toxicity.  
 
5.2 Future directions 
 
Synthesis of additional gabapentin prodrugs that may be immediately intraconverted to 
their parent drug, gabapentin, at pH 7.4 (blood circulation system) by using linkers 
having pKa close to that of the blood circulation (pH 7.4). 
 
 Moreover, In vivo pharmacokinetic studies will be done for both ProD 1 and ProD 2 in 
order to determine the bioavailability and the duration of action of the tested prodrugs. 
 
 Finally, we will evaluate if our newly synthesized prodrugs have pharmacological 
activity before they undergo hydrolysis because they have a programmable release 
manner. 
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 تصنيع ودراسة مواصفات وحركية الدواء المخبرية لطلائع الغابابنتين. 
 إعداد: فاطمة عصام عبد القادر حداد
 رفيق قرمانالدكتور إشراف: البروفيسور 
 الممخص
م من تحد من فعاليتو السريرية؛ وذلك لأن إمتصاصو يت منتظمةحركية دوائية  الغابابنتينيمتمك 
بواسطة ناقل المغذيات منخفض السعة والذي يتواجد في  -Lنوع  الأمنيةخلال نظام نقل الأحماض 
مكان محدود من الجزء العموي للأمعاء الدقيقة. نظام النقل ىذا ىو نظام نقل يحتاج إلى ناقل 
ويحدث لو إشباع؛ وىذا أدى إلى اعتماد حركية الدواء لمغابابنتين عمى الجرعة؛ أي أنو كمما زادت 
 لمغابابنتين. (الأمتصاص)  وافر الحيويالجرعة ينخفض الت
استنادًا إلى نموذج إنزيم كيربي، تم اقتراح ثلاثة طلائع لمغابابنتين يتوقع أن تكون ذات توافر حيوي 
عالي وتمتمك حركية دوائية خطية، عمى النقيض من الغابابنتين، نتيجة لتحسين امتصاصو عبر 
دام الطلائع المقترحة في أشكال صيدلانية مختمفة الانتشار البسيط. علاوة عمى ذلك، يمكن استخ
 بسبب احتمالية قابميتيا لمذوبان في الوسطين العضوي والمائي.
أطياف الأشعة  قياس درجة الإنصيار، تم تحضير وتشخيص ىذه الطلائع المتقرحة عن طريق
لكتمي بالمطياف او كروماتوغرافيا المقترن  تحت الحمراء، والرنين النووي المغناطيسي لمبروتون،
 دواءهعة نقية. و تم دراسة تحمل ىذه الطلائع داخل المختبر إلى نصلمتأكد من أن المركبات الم
ة العالية عمى الكفاءباستخدام كروماتوغرافيا السائل ذات   -دون أي تدخل من الإنزيمات-الأصمي 
، التي 4.7 و8.6  و3 و lCH N1.0 و درجات حموضة مختمفة مثل )Co73( حرارة ثابتة درجة 
تشبو دراجات الحموضة في جسم الإنسان. و قد تم التنبؤ بخصائص ىذه الطلائع الفيزوكيميائية، 
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والامتصاص، والتوزيع، والأيض، والإخراج، والسمية، و قابمتيا لمنفاذ من خلال الحاجز الدموي 
 لمدماغ من خلال برامج معموماتية متعددة.
 1.0التجريبي لطميعة الغابابنتين الأول في حمض الييدروكموريد   وقد تبين أن قيم العمر النصفي
، 75.61كانت  4.7، ودرجة الحموضة 8.6، ودرجة الحموضة 3، ودرجة الحموضة  lCH N
الغابابنتين الثاني ساعة، عمى التوالي. وأيضا تم تحميل طميعة  84.911، و 19.101، و67.71و
 4.7، و8.6، و3حموضة ، ودرجات 1.0 lCH Nفي حمض الييدروكموريد   إلى دوائو الأساسي
ساعة، عمى  2.772، و57.031، و07.22، و3.02وكانت قيم العمر النصفي التجريبي 
التوالي. بالمقابل، كان طميعة الغابابنتين الثالث غير قابل لمذوبان إطلاقا في البيئة الحمضية 
 .4.7ودرجة الحموضة  8.6 ومستقر تماما في درجة الحموضة
وقد أظيرت نتائج تنبؤ خصائص ىذه الطلائع من خلال البرامج المعموماتية أن جميع ىذه الطلائع  
تتوافق مع قاعدة لبنسكي ولدييا خصائص حركية دوائية جيدة وليس لدييا مخاطر عالية من السمية 
 و لدييا القابميو لمنفاذ إلى الجياز العصبي المركزي.
ات ثلاثة طلائع لمغابابنتين و قد بينت نتائج تحمميا الي أن العمر ع و دراسة مواصفلقد تم تصني
النصفي يتأثر بشكل أساسي بالرقم الييدروجيني لموسط والمسافة بين المركزين المتفاعمين (ذرة 
الأكسجين بالييدروكسيل التابعة لمجموعة الكربوكسيل وذرة الكربون بمجموعة الكربونيل بالربطة 
لأول و الثاني في جسم لمرابط. سوف يتم دراسة حركية طميعة الغابابنتين ا akpميدية) وال الأ
 ساب التوفر الحيوي و مدة عمميا.الانسان لح
 
 
 
